Multivalent D-peptide Polymers for A-beta Oligomer Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease are unable to prevent or cure the condition, as they fail to effectively target and reduce toxic A-beta oligomers and fibrils, which are responsible for the progression of the disease, and there is a lack of diagnostic tools for early detection before symptoms appear.
Innovation Solution
Development of multivalent amyloid-beta-binding polymeric substances composed of D-amino acids that specifically bind to A-beta oligomers with high affinity, preventing their reproduction and destruction, and serving as probes for early diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monovalent A-beta ligands are used, then the affinity for A-beta oligomers is limited, but the complexity of the substance is low
Solution Approach 1:
The patent combines multiple A-beta binding ligands into a single multivalent polymer structure. The polymer contains multiple binding sites that can simultaneously interact with A-beta oligomers, thereby increasing the overall binding affinity and effectiveness compared to monovalent ligands while maintaining a manageable molecular structure through systematic design.
Solution Approach 2:
The invention creates composite polymeric structures that integrate multiple binding motifs within a single molecule. These composite structures combine the advantages of different ligand designs and achieve enhanced binding properties that exceed the sum of individual monovalent ligands, resolving the contradiction between affinity and complexity.
2Ease of operation
If existing drugs are used, then some symptoms are alleviated, but the disease progression cannot be slowed or cured
Solution Approach 1:
The patent designs ligands that specifically copy and bind to the structure of toxic A-beta oligomers. By creating molecules that mimic the oligomer structure, the multivalent polymers can selectively recognize and bind to these toxic forms with high affinity, enabling both symptom relief and potential disease modification through targeted intervention.
Solution Approach 2:
The invention changes the binding parameters by using multivalent structures with multiple interaction sites. This increases the binding strength and specificity for A-beta oligomers compared to monovalent ligands, transforming the interaction from weak and non-specific to strong and selective, thereby achieving both symptomatic relief and disease-modifying effects.
3Reliability
If A-beta monomer concentration is reduced, then oligomer formation is prevented, but the effect is insufficient for treating established disease
Solution Approach 1:
The patent employs multivalent ligands that can bind to A-beta oligomers before they undergo prion-like multiplication and form larger aggregates. By acting early in the oligomer stage with high-affinity multivalent binding, the ligands prevent the exponential amplification of toxic species, achieving effective prevention and treatment with manageable ligand concentrations.
Solution Approach 2:
The multivalent polymers act as intermediary molecules that bridge and stabilize A-beta oligomers in a non-toxic bound state. This intermediary binding prevents the oligomers from interacting with cellular targets and propagating, effectively neutralizing their toxicity while maintaining a manageable concentration of therapeutic agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These polymers effectively bind to A-beta oligomers, reducing their formation and multiplication, and can be used for early diagnosis and treatment of Alzheimer's disease, offering a potential cure and diagnostic tool.
Implementation Method 1
The polymers according to the invention bind both the small, freely diffusible A-beta oligomers and larger A-beta oligomers through to fibrils
Implementation Method 2
The polymers constructed according to the invention from monomers which in turn bind to A-beta oligomers show clear, synergetic effects with regard to their selectivity and affinity for the A-beta oligomers
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to novel multivalent amyloid-beta-binding polymeric substances consisting of a plurality of substances joined together which per se already have amyloid-beta-binding properties, and the use of these substances, called "polymers" hereinbelow, especially in medicine.